Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein
- PMID: 7506298
- DOI: 10.1099/0022-1317-74-12-2567
Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein
Abstract
To study the conformational requirements of epitopes from a conserved antigenic area (area II) of respiratory syncytial (RS) virus fusion (F) glycoprotein, peptides of increasing length containing amino acids essential for these epitopes were synthesized. The synthetic peptides were tested for binding to a panel of neutralizing monoclonal antibodies (MAbs) for this area as well as to rabbit hyperimmune and human convalescent antisera. Antibody binding was dependent on peptide length; thus, a 61-residue peptide spanning amino acids 215 to 275 of the F1 subunit (peptide F215-275) reacted with more antibodies than a shorter (41-residue) peptide F235-275, and this one with more than the (21-residue) peptide F255-275. Most human convalescent sera contained antibodies that reacted with peptides F215-275 and F235-275 but failed to react with F255-275. The results of antibody binding could be related to the structure adopted by the peptides in solution, as determined by circular dichroism spectroscopy and susceptibility of peptides to trypsin digestion. Pretreatment of peptide F215-275 with SDS abolished reactivity with certain MAbs, supporting the notion that higher order structures were needed for antibody binding. High titre anti-peptide antisera were induced in rabbits inoculated with the peptides; however, these sera failed to react with the native F molecule. In mice, only the largest F215-275 peptide induced an anti-peptide response, but their sera reacted poorly with the native F protein and the animals were not protected against an RS virus challenge. These results illustrate the potential use of synthetic peptides in studies of the F protein physical and antigenic structures as well as the problems in designing synthetic RS virus vaccines.
Similar articles
-
Structure-Based Vaccine Antigen Design.Annu Rev Med. 2019 Jan 27;70:91-104. doi: 10.1146/annurev-med-121217-094234. Annu Rev Med. 2019. PMID: 30691364 Free PMC article. Review.
-
Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.J Gen Virol. 1993 Dec;74 ( Pt 12):2559-65. doi: 10.1099/0022-1317-74-12-2559. J Gen Virol. 1993. PMID: 7506297
-
Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus.J Gen Virol. 1991 May;72 ( Pt 5):1051-8. doi: 10.1099/0022-1317-72-5-1051. J Gen Virol. 1991. PMID: 2033389
-
Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.J Gen Virol. 1992 Sep;73 ( Pt 9):2225-34. doi: 10.1099/0022-1317-73-9-2225. J Gen Virol. 1992. PMID: 1383404
-
Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein.J Gen Virol. 1997 Oct;78 ( Pt 10):2411-8. doi: 10.1099/0022-1317-78-10-2411. J Gen Virol. 1997. PMID: 9349459 Review. No abstract available.
Cited by
-
Global progress in clinical research on human respiratory syncytial virus vaccines.Front Microbiol. 2024 Sep 2;15:1457703. doi: 10.3389/fmicb.2024.1457703. eCollection 2024. Front Microbiol. 2024. PMID: 39286350 Free PMC article. Review.
-
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.Pathogens. 2025 Jan 21;14(2):104. doi: 10.3390/pathogens14020104. Pathogens. 2025. PMID: 40005481 Free PMC article. Review.
-
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens.J Immunol Res. 2015;2015:156241. doi: 10.1155/2015/156241. Epub 2015 Oct 7. J Immunol Res. 2015. PMID: 26526043 Free PMC article. Review.
-
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.J Mol Biol. 2011 Jun 24;409(5):853-66. doi: 10.1016/j.jmb.2011.04.044. Epub 2011 Apr 27. J Mol Biol. 2011. PMID: 21549714 Free PMC article.
-
Structure-Based Vaccine Antigen Design.Annu Rev Med. 2019 Jan 27;70:91-104. doi: 10.1146/annurev-med-121217-094234. Annu Rev Med. 2019. PMID: 30691364 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources